You are here: Industry Insights > STI-1499

News List

Sorrento gets US FDA nod for Phase 1 clinical trial of neutralising antibody in COVID-19 patients expresspharma
September 18, 2020
Sorrento had earlier informed that COVI-GUARD (STI-1499) demonstrated 100 per cent in vitro neutralizing effect against SARS-CoV-2.
Sorrento to Acquire SmartPharm contractpharma
July 27, 2020
Gains non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases.
Potential Anti-SARS-CoV-2 Antibody Able to Inhibit In Vitro Virus Infection in Preclinical Studies americanpharmaceuticalreview
May 19, 2020
Sorrento Therapeutics announced anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody concentration.
Sorrento’s antibody completely blocks Covid-19 in-vitro pharmaceutical-technology
May 19, 2020
Sorrento Therapeutics has reported that its Covid-19 therapeutic antibody candidate, STI-1499, can completely block the viral infection in-vitro during preclinical studies.